For primær forebyggelse kan CPMP imidlertid ikke godkende, at “ myokardial revaskularisering ” anføres i indikationsafsnittet, da virkningen af revaskularisering afhænger af klinisk praksis og bør anses for en følge af risikoen forbundet med myokardieinfarktreduktion.
However, as for primary prevention, the CPMP disagreed to mention “ myocardial revascularisation” in the indication section as the effects of revascularisation depends on medical practice and should be considered as a consequence of the myocardial infarction reduction risk.